Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Financial information provided by Financial Modelling Prep. Logos provided by Logo.dev.
Neuren Pharmaceuticals has announced a new on-market share buy-back programme to repurchase up to 5% of its shares over the next 12 months. The board indicated that the shares are currently undervalued.
